Onconetix Inc (ONCO) - Total Liabilities
Based on the latest financial reports, Onconetix Inc (ONCO) has total liabilities worth $3.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Onconetix Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Onconetix Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Onconetix Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Onconetix Inc (ONCO) total assets.
Onconetix Inc Competitors by Total Liabilities
The table below lists competitors of Onconetix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanti Overseas (India) Limited
NSE:SHANTI
|
India | Rs142.01 Million |
|
Lucky Minerals Inc
V:LKY
|
Canada | CA$8.24 Million |
|
Creo Medical Group PLC
LSE:CREO
|
UK | GBX9.10 Million |
|
Aesthetic Medical International Holdings Group Limited
NASDAQ:PAIYY
|
USA | $554.12 Million |
|
Upgrade Invest Nordic AB
ST:UPGRAD
|
Sweden | Skr42.00K |
|
Biodexa Pharmaceticals
NASDAQ:BDRX
|
USA | $6.76 Million |
|
Midsona AB (publ)
ST:MSON-A
|
Sweden | Skr1.46 Billion |
|
RightBridge Ventures Group AB
ST:RIGHTB
|
Sweden | Skr15.38 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Onconetix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ONCO equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Onconetix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Onconetix Inc (2019–2025)
The table below shows the annual total liabilities of Onconetix Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.16 Million | -50.67% |
| 2024-12-31 | $18.57 Million | -78.43% |
| 2023-12-31 | $86.11 Million | +2095.41% |
| 2022-12-31 | $3.92 Million | +139.45% |
| 2021-12-31 | $1.64 Million | +1991.84% |
| 2020-12-31 | $78.31K | -5.22% |
| 2019-12-31 | $82.62K | -- |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other … Read more